BioSpace News Archive

Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of November 30, 2023, the grant of restricted stock units covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to twelve new employees.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Retractable Technologies, Inc. reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 shares of Arcutis’ common stock to 7 newly hired employees.

Shanghai Junshi Biosciences Co., Ltd announced that the TGA has accepted the NCE application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

Biohaven Ltd. (NYSE: BHVN) announced today that it is presenting expanded EEG and safety data for BHV-7000 at the 2023 American Epilepsy Society (AES) Annual Meeting, taking place December 1-5, 2023, in Orlando, Florida.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making Inducement Grants Under NASDAQ Listing Rule 5635 in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations.

Aimei Health Technology Co., Ltd (NASDAQ: AFJKU, the “Company”) announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit.

Eli Lilly and Company announced that the U.S. Food and Drug Administration approved Jaypirca® for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor and a BCL-2 inhibitor.